NRG1 Fusions in Lung and GI Cancers

Opinion
Video

Alexander I. Spira, MD, PhD, and Joshua K. Sabari, MD, discuss the prevalence of NRG1 fusions in pulmonary and gastrointestinal solid tumors and provide an overview of treatment practices.

Educational support for this activity provided by Merus.

Recent Videos
Higher, durable rates of response to frontline therapy are needed to potentially improve long-term survival among patients with non–small cell lung cancer.
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content
Neoadjuvant Therapy Trumps Surgery in NSCLC Debate

Neoadjuvant Therapy Trumps Surgery in NSCLC Debate

ONCOLOGY Staff
September 30th 2024
Article

The University of Chicago goes against Northwestern Medicine to see who will be crowned the winner in the NSCLC debate.

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

Optimizing NSCLC Outcomes Via Technological Advances in Radiation Oncology

Terence T. Sio, MD, MS
June 3rd 2024
Podcast

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

Findings from the phase 3 LAURA trial support the approval of osimertinib for advanced EGFR-mutated NSCLC.

FDA Approves Osimertinib in Advanced EGFR+ NSCLC

Roman Fabbricatore
September 25th 2024
Article

Findings from the phase 3 LAURA trial support the approval of osimertinib for advanced EGFR-mutated NSCLC.

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

Moving The Needle in Lung Cancer Management With Robotic-Assisted Surgery

Richard Lazzaro, MD
April 22nd 2024
Podcast

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

HERTHENA-Lung02 investigators will present further data from the trial at a future medical meeting.

HER3-DXd Significantly Improves PFS Vs Chemo in Advanced EGFR+ NSCLC

Russ Conroy
September 17th 2024
Article

HERTHENA-Lung02 investigators will present further data from the trial at a future medical meeting.

CheckMate 77T Highlights EFS Benefit in Perioperative Nivolumab in Resectable NSCLC

CheckMate 77T Highlights EFS Benefit in Perioperative Nivolumab in Resectable NSCLC

Kyle Doherty
September 15th 2024
Article

A median EFS of 40.1 months was noted in patients resectable NSCLC given perioperative nivolumab vs placebo.